Initial experience with golimumab in clinical practice for ulcerative colitis
Rev. esp. enferm. dig
; 108(3): 129-132, mar. 2016. tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-148605
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Background:
Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.Purpose:
To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice.Methods:
Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg.Results:
Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%.Conclusions:
In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied (AU)RESUMEN
No disponible
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Colite Ulcerativa
/
Receptores do Fator de Necrose Tumoral
/
Fator 1 Associado a Receptor de TNF
/
Anticorpos Monoclonais
Tipo de estudo:
Estudo observacional
/
Fatores de risco
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Rev. esp. enferm. dig
Ano de publicação:
2016
Tipo de documento:
Artigo
Instituição/País de afiliação:
Complejo Hospitalario de Jaén/Spain
/
Hospital Infanta Elena/Spain
/
Hospital Juan Ramón Jiménez/Spain
/
Hospital Reina Sofía/Spain
/
Hospital Torrecárdenas/Spain
/
Hospital Virgen Macarena/Spain
/
Hospital Virgen de las Nieves/Spain
/
Hospital Virgen del Rocío/Spain
/
Hospital de Poniente/Spain